US-based gene therapy company Tocagen has agreed to provide exclusive rights for ApolloBio to develop and commercialise its drug candidate, Toca 511 & Toca FC, in the greater China region.

The licensing agreement involves ApolloBio’s subsidiary Beijing Apollo Venus Biomedical Technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Toca 511 & Toca FC is a cancer immunotherapy being developed for recurrent high grade glioma (HGG), a type of brain tumour.

Currently being evaluated in the Phase III Toca 5 clinical trial, the drug candidate secured breakthrough therapy status from the US Food and Drug Administration, and the European Medicines Agency has granted priority medicines designation.

Tocagen will receive $16m upfront and another $4m based on certain near-term development milestones such as Toca 5 trial completion.

“As an innovative biopharmaceutical company in China, ApolloBio is well positioned to leverage China’s recent regulatory changes supporting the development of new medicines.”

Upon achieving further development and commercial milestones, the company will be eligible for an additional $111m and tiered royalty payments on net sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tocagen CEO Marty Duvall said: “As an innovative biopharmaceutical company in China, ApolloBio is well positioned to leverage China’s recent regulatory changes supporting the development of new medicines.

“ApolloBio brings valuable regional expertise in product development, regulation and healthcare access, positioning our lead product to advance towards patients in the greater China region as quickly and efficiently as possible.”

Under the agreement, ApolloBio will bear all development and commercialisation costs associated with the greater China region.

The deal is subject to customary conditions but it is expected to become effective from the second quarter of this year.